Review Paper of Dostarlimab
Shrenik M. Mane, Jivan S. Kharat, Shubhangi J. Shid
Dostarlimab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor from interacting with its ligands, PD-L1 and PD-L2. This interaction between PD-1 and its ligands can suppress the immune system's ability to attack cancer cells. By blocking this interaction, dostarlimab can help to unleash the immune system to fight cancer.Dostarlimab is also generally well-tolerated with a relatively mild side effect profile. The most common side effects are fatigue, nausea, diarrhea, and rash. These side effects are typically mild and manageable, and they often go away on their own or with supportive care.Dostarlimab is a relatively new drug, and it is still too early to say what its long-term safety and efficacy are. However, the results from clinical trials so far have been very promising. We will discuss the mechanism of action, trial phase performance and side effects of Dostarlimab drug.
Article Details
Unique Paper ID: 161881

Publication Volume & Issue: Volume 10, Issue 6

Page(s): 487 - 492
Article Preview & Download

Share This Article

Conference Alert


AICTE Sponsored National Conference on Smart Systems and Technologies

Last Date: 25th November 2023

SWEC- Management


Last Date: 7th November 2023

Go To Issue

Call For Paper

Volume 10 Issue 1

Last Date for paper submitting for March Issue is 25 June 2023

About Us enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on

Social Media

Google Verified Reviews